Human leukocyte antigens in Indian patients with chronic myeloid leukemia.

Abstract:

:In chronic myeloid leukemia (CML), experimental studies using synthetic peptides identical to the bcr-abl fusion region have revealed the capability of specific peptides to bind to human leukocyte antigen (HLA) class I molecules (HLA-A2, A3, A11, B8) and class II molecules (HLA-DR1, DR2, DR3, DR4 and DR11). Individuals expressing HLA-A3, B8 or DR4 have a diminished risk for the development of CML in Caucasian populations. A statistically significant increase in the frequency of Cw3 and Cw4 antigens in Caucasians and European CML patients has been reported. However, HLA associations in CML have not been reported in India. In lieu of the allelic diversity of HLA in the Indian population, the present study assessed the possibility of an association of HLA molecules in Indian patients with CML. HLA A, B, C and DRB1 antigen associations in 180 clinically diagnosed Indian CML patients (aged 17 - 54 years) were analysed and compared with age-matched (n = 100) healthy individuals from the same ethnic background. In the HLA class I antigen distribution, a significant decrease was observed in HLA-A11 (25.6% versus 39%; P = 0.027, odds ratio (OR) = 0.54, 95% confidence interval (CI) = 0.31 - 0.94) and HLA-Cw6 (7.8% versus 20%; P = 0.005, OR = 0.34, 95% CI = 0.15 - 0.74). Among the DRB1 alleles, HLA-DRB1*13 (7.8% versus 17%; P = 0.031, OR = 0.41, 95% CI = 0.18 - 0.93) was decreased in CML patients. However, the differences for HLA-A11 (P(c) = 0.351) and DRB1*13 (P(c) = 0.403) did not remain significant after the application of a correction factor for the P-value. These results suggest that the development of CML is apparently associated with HLA phenotypes specific to each population and indicate that expression of HLA-Cw6 may result in a protective effect on CML acquisition in the Indian population.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Chhaya SU

doi

10.1080/10428190500287117

keywords:

subject

Has Abstract

pub_date

2006-02-01 00:00:00

pages

291-5

issue

2

eissn

1042-8194

issn

1029-2403

pii

L086G56784776373

journal_volume

47

pub_type

杂志文章
  • Involvement of HLA Antigens, Interleukin 2 Receptor and B-Cell Growth Factor in Interferon Action in Hairy Cell Leukemia.

    abstract::Little is known about the mechanism(s) by which alpha-interferon (aIFN), when used as a biotherapeutic agent, suppresses the malignant cells and restores the normal phenotype of cells in patients with hairy cell leukemia (HCL). In previous studies using scanning electron microscopy (SEM) we found that alFN induced uni...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009053529

    authors: Gamliel H,Gurfel D,Wu SH,Salzberg S,Golomb HM

    更新日期:1990-01-01 00:00:00

  • The Wilms tumour gene WT1 in leukaemia.

    abstract::The WT1 gene is essential for kidney development and is mutated in some Wilms tumours. It is also expressed at a high level in many acute leukaemias and in some haematopoietic progenitor cells, and mutations have been found in leukaemias. The function of WT1, which is a zinc finger protein and has domains characterist...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709059677

    authors: Pritchard-Jones K,King-Underwood L

    更新日期:1997-10-01 00:00:00

  • The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.

    abstract::Chronic myeloid leukemia (CML) is rare among children and adolescents. The early molecular response (EMR) is an important prognostic significance for adult CML patients. This study explored the impact of EMR on the prognosis in 40 children and adolescents with CML-CP treated with imatinib (IM). Our results showed that...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1422860

    authors: Shao H,Zeng Z,Cen J,Zhang J,Bai S,Wu C,Gong Y,Wang Y,Qiu H,Chen S,Pan J

    更新日期:2018-09-01 00:00:00

  • Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo.

    abstract::Glutamate is the major excitatory neurotransmitter of the nervous system. We previously found that glutamate activates normal human T-cells, inducing their adhesion and chemotaxis, via its glutamate receptors of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype 3 (GluR3) expressed in these ce...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902878448

    authors: Ganor Y,Grinberg I,Reis A,Cooper I,Goldstein RS,Levite M

    更新日期:2009-06-01 00:00:00

  • The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.

    abstract::Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this s...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428190109057927

    authors: White JD,Wharfe G,Stewart DM,Maher VE,Eicher D,Herring B,Derby M,Jackson-Booth PG,Marshall M,Lucy D,Jain A,Cranston B,Hanchard B,Lee CC,Top LE,Fleisher TA,Nelson DL,Waldmann TA

    更新日期:2001-01-01 00:00:00

  • Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?

    abstract::The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lena...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.496017

    authors: Brown JR

    更新日期:2010-08-01 00:00:00

  • The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription.

    abstract::Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile. Statins, a dyslipidemia drug, were reported to potentiate imatinib's antileukemic effect. However, analysis of imatinib combined with statins is lacking. We have retrospectively analyzed the normalizati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1228928

    authors: Ellis M,Krashin E,Hamburger-Avnery O,Gan S,Elis A,Ashur-Fabian O

    更新日期:2017-05-01 00:00:00

  • Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.

    abstract::Arsenic trioxide, believed to be a carcinogen and a teratogen, has found its niche in the treatment of acute promyelocytic leukemia (APL). APL is a disease affecting young patients. Post-treatment fertility and outcome of pregnancy are always a concern in a disease with high cure rates. We report a case series of six ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.679936

    authors: Gupta S,Bagel B,Gujral S,Subramanian PG,Khattry N,Menon H,Nair R

    更新日期:2012-11-01 00:00:00

  • Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience.

    abstract::Little is known about disparities in myelodysplastic syndromes (MDS). We performed a retrospective chart review of patients with MDS (n = 252) evaluated at the University of Maryland Greenebaum Cancer Center between 2000 and 2010. The median age at diagnosis was 65 years, which was lower than the median age of 76 year...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.710904

    authors: Zandberg DP,Hendrick F,Vannorsdall E,Bierenbaum J,Tidwell ML,Ning Y,Zhao XF,Davidoff AJ,Baer MR

    更新日期:2013-02-01 00:00:00

  • IKZF1 rs4132601 polymorphism and acute lymphoblastic leukemia susceptibility: a meta-analysis.

    abstract::Several studies have been conducted to examine the association between IKZF1 rs4132601 polymorphism and acute lymphoblastic leukemia (ALL) risk. However, the conclusions remain controversial. We therefore performed a meta-analysis. PubMed, Embase, Web of Science, Weipu and Chinese Biomedical Literature (CBM) databases...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析

    doi:10.3109/10428194.2014.939965

    authors: Li S,Ren L,Fan L,Wang G

    更新日期:2015-04-01 00:00:00

  • Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.

    abstract::Considering conflicting data on CDKN2A/B deletion in ALL, this study to assess its prognostic significance as an independent marker in a total of 96 pediatric B and T-ALL cases was planned. The overall frequency of CDKN2A/B deletion was 44% (n = 43) with 36% (30/83) in B-ALL and 100% (13/13) in T-ALL. CDKN2A/B deletio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1482542

    authors: Kathiravan M,Singh M,Bhatia P,Trehan A,Varma N,Sachdeva MS,Bansal D,Jain R,Naseem S

    更新日期:2019-02-01 00:00:00

  • Acute myeloid leukemia with inv(8)(p11q13).

    abstract::A patient with acute monoblastic leukemia (AML M5a) and the pericentric inversion inv(8)(p11q13) as well as additional chromosome abnormalities in her bone marrow cells is described. This is the fourth known case of inv(8)(p11q13)-positive acute leukemia, and the second such case in which gain of 1q material occurred ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009113397

    authors: Panagopoulos I,Teixeira MR,Micci F,Hammerstrøm J,Isaksson M,Johansson B,Mitelman F,Heim S

    更新日期:2000-11-01 00:00:00

  • Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas.

    abstract::B cell non-Hodgkin lymphomas (B-NHLs) are the most common adult hematological cancers and many remain incurable. Development of chemotherapy regimens is confounded by the prevalence of B-NHL in older, frailer patients and the chemo-protective tumor microenvironment. Although biological therapies such as rituximab have...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.939962

    authors: Hayden RE,Kussaibati R,Cronin LM,Pratt G,Roberts C,Drayson MT,Bunce CM

    更新日期:2015-04-01 00:00:00

  • Central Nervous System (CNS) Involvement in Acute Nonlymphocytic Leukemia (ANLL).

    abstract::The incidence of central nervous system (CNS) involvement and effects of therapy were reviewed in 42 consecutive pediatric patients with acute nonlymphocytic leukemia (ANLL). The morphology of ileukemic cells was considered M1 in 13, M2 in 7, M3 in 5, M4 in 8, and M5 in 9. Two patients with M5 morphology presented wit...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009042513

    authors: Barrios N,Tebbi CK,Freeman AI

    更新日期:1990-01-01 00:00:00

  • Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.

    abstract::Myeloproliferation, myeloaccumulation (decreased apoptosis), inflammation, bone marrow fibrosis and angiogenesis are cardinal features of the Philadelphia-negative chronic myeloproliferative neoplasms: essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Histone deacetylases (HDACs) ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.597905

    authors: Skov V,Larsen TS,Thomassen M,Riley CH,Jensen MK,Bjerrum OW,Kruse TA,Hasselbalch HC

    更新日期:2012-01-01 00:00:00

  • Expression of sialosyl-T and disialosyl-T antigens in erythroid cells.

    abstract::Expression of T, sialosyl-T and disialosyl-T antigens on normal blood and bone marrow cells as well as transformed cells was examined using specific monoclonal antibodies and multidimensional flow cytometry. Both anti-sialosyl-T (QSH1) and anti-disialosyl-T (QSH2) monoclonal antibodies aggregated erythrocytes. The ant...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709039027

    authors: Muroi K,Amemiya Y,Sievers EL,Miura Y,Hakamori SI,Loken MR

    更新日期:1997-05-01 00:00:00

  • Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy.

    abstract::We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries from northern Italy were used to identify patients with HL diagnosed from 2006 to 2008. Computed tomography (CT) and PET scans were collected before tr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.580475

    authors: Luminari S,Cesaretti M,Tomasello C,Guida A,Bagni B,Merli F,Postiglione R,Mangone L,Versari A,Re F,De Lisi V,Ruffini L,Ferretti S,Cuneo A,Federico M

    更新日期:2011-09-01 00:00:00

  • Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors.

    abstract::To define the initial characteristics and prognostic factors of patients with conjunctival low-grade malignant lymphoma, all patients treated for low-grade lymphoma with initial conjunctival involvement were reviewed. Forty-nine cases were selected, including 45 cases with exclusive ophthalmologic conjunctival involve...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500518966

    authors: Meunier J,Lumbroso-Le Rouïc L,Dendale R,Vincent-Salomon A,Asselain B,Arnaud P,Némati F,Fourquet A,Desjardins L,Plancher C,Levy C,Chaoui D,Validire P,Decaudin D

    更新日期:2006-07-01 00:00:00

  • Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis.

    abstract::The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509051698

    authors: Bueso-Ramos CE,Manshouri T,Haidar MA,Huh YO,Keating MJ,Albitar M

    更新日期:1995-03-01 00:00:00

  • Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings.

    abstract::We studied the outcome of 213 patients who received allo-HSCT for hematological malignancies, 121 (57%) from HLA identical siblings, 63 (29%) from 10/10 HLA identical unrelated donors and 29 (14%) from 9/10 HLA mismatched unrelated donors. Engraftment was lower in the 9/10 HLA group (90%) than in the 10/10 HLA group (...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.944518

    authors: Michallet M,Sobh M,Serrier C,Morisset S,Labussière H,Ducastelle S,Barraco F,Gilis L,Thomas X,Nicolini FE

    更新日期:2015-04-01 00:00:00

  • Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.

    abstract::We report follow-up information on 69 hairy cell leukemia (HCL) patients treated with interferon alfa-2b (IFN) as primary treatment from 1983 to 1986. Follow-up through April, 1993 shows that only 14 patients have expired. Forty-seven of the 61 patients completing the intended 12 or more months of initial IFN treatmen...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Spielberger RT,Mick R,Ratain MJ,Golomb HM

    更新日期:1994-01-01 00:00:00

  • Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.

    abstract::The recurring translocation t(1;19) (q23;p13) with TCF3-PBX1 rearrangements are uncommon in adult acute lymphoblastic leukemia (ALL), and their prognostic impact remains to be described in the era of modern chemotherapies. We investigated 427 adult patients with newly diagnosed pre-B ALL, 16 (4%) had t(1;19)(q23;p13) ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1824071

    authors: Yilmaz M,Kantarjian HM,Toruner G,Yin CC,Kanagal-Shamanna R,Cortes JE,Issa G,Short NJ,Khoury JD,Garcia-Manero G,Ravandi F,Kadia T,Konopleva M,Wierda WG,Jain N,Estrov Z,Sasaki K,Pierce S,O'Brien SM,Jabbour EJ

    更新日期:2021-01-01 00:00:00

  • CD105 (endoglin) expression on hematopoietic stem/progenitor cells.

    abstract::Endoglin (CD105) is a component of the transforming growth factor-beta (TGF-beta) receptor (TGF-betaR) complex. Together with betaglycan, CD105 is considered as a TGF-betaR accessory molecule (also called TGF-betaRIII), but its functions in the receptor-ligand interactions are still poorly understood. A small subset o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109097744

    authors: Pierelli L,Bonanno G,Rutella S,Marone M,Scambia G,Leone G

    更新日期:2001-11-01 00:00:00

  • The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.

    abstract::Several studies have indicated that age, hemoglobin and serum albumin are among the most important prognostic factors for survival of patients with Waldenstrom's macroglobulinemia (WM). Furthermore, recent data indicate that serum b2-microglobulin may be also significant. The recently proposed International Staging Sy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001687512

    authors: Dimopoulos M,Gika D,Zervas K,Kyrtsonis M,Symeonidis A,Anagnostopoulos A,Bourantas K,Matsouka C,Pangalis G

    更新日期:2004-09-01 00:00:00

  • Hepatitis C virus, B-cell proliferation and lymphomas.

    abstract::Accumulating evidence support a role for hepatitis C virus (HCV) in the pathogenesis of human lymphoproliferative disorders. Clonal expansions of B lymphocytes have been prevalently detected in the bone marrow, in the liver and in the peripheral blood of HCV-infected patients. Epidemiologic studies have associated HCV...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290016845

    authors: Gasparotto D,De Re V,Boiocchi M

    更新日期:2002-04-01 00:00:00

  • Extranodal NK/T-cell lymphoma mimicking cellulitis.

    abstract::NK/T-cell lymphoma is difficult to diagnose because there is no characteristic cytology to help the diagnosis in tissue sections, particularly when there is polymorphic cellular infiltration in the early stage of the disease. However, the nasal type of extranodal NK/T-cell lymphoma has a characteristic histologic patt...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001652313

    authors: Jia H,Sun T

    更新日期:2004-07-01 00:00:00

  • Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.

    abstract::A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the to...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/10428190290021339

    authors: Mainwaring MG,Rimsza LM,Chen SF,Gomez SP,Weeks FW,Reddy V,Lynch J,May WS,Kahn S,Moreb J,Leather H,Braylan R,Rowe TC,Fieniewicz KJ,Wingard JR

    更新日期:2002-05-01 00:00:00

  • Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.

    abstract::The occurrence of acute myeloid leukemia (AML) as a secondary tumor has been frequently reported in patients who received various chemotherapy regimens for hematologic malignancies wile the concomitant development of chronic lymphoproliferative diseases (CLD) and AML in previously untreated patients is extremely rare....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097666

    authors: Montefusco E,Fazi F,Cordone I,Ariola C,Nanni M,Spadea A,Spiriti MA,Fenu S,Mandelli F,Petti MC

    更新日期:2001-02-01 00:00:00

  • Identification and validation of a prognostic 8-gene signature for acute myeloid leukemia.

    abstract::In the present study, we aimed to identify some genes closely related to AML prognosis and investigate their potential roles. RNA-seq data of AML samples were accessed from the TCGA database and then analyzed in the Wilcox test. AML survival-related genes were selected and an 8-gene signature-based risk score model wa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1742898

    authors: Zhang Y,Xiao L

    更新日期:2020-08-01 00:00:00

  • Joint occurrence of Merkel cell carcinoma and non-Hodgkin lymphomas in four Nordic countries.

    abstract::The objective of this study was to assess the reciprocal association between non-Hodgkin lymphoma (NHL) and Merkel cell carcinoma (MCC) using the data of four Nordic Cancer Registries. Data for this study were drawn from the Danish, Finnish, Norwegian, and Swedish cancer registries. Standardized incidence ratios (SIRs...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1040010

    authors: Koljonen V,Rantanen M,Sahi H,Mellemkjær L,Hansen BT,Chen T,Hemminki K,Pukkala E

    更新日期:2015-01-01 00:00:00